| Heart disease and stroke statistics—2014 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ... circulation 129 (3), e28-e292, 2014 | 31373* | 2014 |
| Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease H Schunkert, IR König, S Kathiresan, MP Reilly, TL Assimes, H Holm, ... Nature genetics 43 (4), 333-338, 2011 | 2216 | 2011 |
| A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants LG Fritsche, W Igl, JNC Bailey, F Grassmann, S Sengupta, ... Nature genetics 48 (2), 134-143, 2016 | 1456 | 2016 |
| Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial U Chakravarthy, SP Harding, CA Rogers, SM Downes, AJ Lotery, ... Ophthalmology 119 (7), 1399-1411, 2012 | 951 | 2012 |
| Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results JA Haller, F Bandello, R Belfort Jr, MS Blumenkranz, M Gillies, J Heier, ... Ophthalmology 118 (12), 2453-2460, 2011 | 890 | 2011 |
| Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial RE MacLaren, M Groppe, AR Barnard, CL Cottriall, T Tolmachova, ... The Lancet 383 (9923), 1129-1137, 2014 | 887 | 2014 |
| Seven new loci associated with age-related macular degeneration Nature genetics 45 (4), 433-439, 2013 | 863 | 2013 |
| Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial U Chakravarthy, SP Harding, CA Rogers, SM Downes, AJ Lotery, ... The Lancet 382 (9900), 1258-1267, 2013 | 815 | 2013 |
| A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy EM Stone, AJ Lotery, FL Munier, E Héon, B Piguet, RH Guymer, ... Nature genetics 22 (2), 199-202, 1999 | 539 | 1999 |
| Prevalence of age-related macular degeneration in Europe: the past and the future JM Colijn, GHS Buitendijk, E Prokofyeva, D Alves, ML Cachulo, ... Ophthalmology 124 (12), 1753-1763, 2017 | 538 | 2017 |
| Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma G Thorleifsson, GB Walters, AW Hewitt, G Masson, A Helgason, A DeWan, ... Nature genetics 42 (10), 906-909, 2010 | 457 | 2010 |
| Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 … S Sivaprasad, AT Prevost, JC Vasconcelos, A Riddell, C Murphy, J Kelly, ... The Lancet 389 (10085), 2193-2203, 2017 | 400 | 2017 |
| Central serous chorioretinopathy: an update on pathogenesis and treatment M Gemenetzi, G De Salvo, AJ Lotery Eye 24 (12), 1743-1756, 2010 | 387 | 2010 |
| Missense variations in the fibulin 5 gene and age-related macular degeneration EM Stone, TA Braun, SR Russell, MH Kuehn, AJ Lotery, PA Moore, ... New England Journal of Medicine 351 (4), 346-353, 2004 | 383 | 2004 |
| Central serous chorioretinopathy: towards an evidence-based treatment guideline TJ Van Rijssen, EH Van Dijk, S Yzer, K Ohno-Matsui, JEE Keunen, ... Progress in retinal and eye research 73, 100770, 2019 | 370 | 2019 |
| Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus Y Lu, V Vitart, KP Burdon, CC Khor, Y Bykhovskaya, A Mirshahi, ... Nature genetics 45 (2), 155-163, 2013 | 356 | 2013 |
| Defining response to anti-VEGF therapies in neovascular AMD WM Amoaku, U Chakravarthy, R Gale, M Gavin, F Ghanchi, J Gibson, ... Eye 29 (6), 721-731, 2015 | 352 | 2015 |
| Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity V Turcot, Y Lu, HM Highland, C Schurmann, AE Justice, RS Fine, ... Nature genetics 50 (1), 26-41, 2018 | 338 | 2018 |
| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 313 | 2022 |
| Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment DHW Steel, AJ Lotery Eye 27 (1), S1-S21, 2013 | 299 | 2013 |
